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Abstract
Background: Many genome-wide association studies focus on associating single loci with target phenotypes.
However, in the setting of rare variation, accumulating sufficient samples to assess these associations can be
difficult. Moreover, multiple variations in a gene or a set of genes within a pathway may all contribute to the
phenotype, suggesting that the aggregation of variations found over the gene or pathway may be useful for
improving the power to detect associations.
Results: Here, we present a method for aggregating single nucleotide polymorphisms (SNPs) along biologically
relevant pathways in order to seek genetic associations with phenotypes. Our method uses all available genetic
variants and does not remove those in linkage disequilibrium (LD). Instead, it uses a novel SNP weighting scheme
to down-weight the contributions of correlated SNPs. We apply our method to three cohorts of patients taking
warfarin: two European descent cohorts and an African American cohort. Although the clinical covariates and key
pharmacogenetic loci for warfarin have been characterized, our association metric identifies a significant association
with mutations distributed throughout the pathway of warfarin metabolism. We improve dose prediction after
using all known clinical covariates and pharmacogenetic variants in VKORC1 and CYP2C9. In particular, we find that
at least 1% of the missing heritability in warfarin dose may be due to the aggregated effects of variations in the
warfarin metabolic pathway, even though the SNPs do not individually show a significant association.
Conclusions: Our method allows researchers to study aggregative SNP effects in an unbiased manner by not
preselecting SNPs. It retains all the available information by accounting for LD-structure through weighting, which
eliminates the need for LD pruning.
Accurate prediction of clinical phenotypes, such as dis-
ease manifestations or drug therapeutic response, using
genotype data is a fundamental challenge in translational
biology. A primary method for establishing phenotype-
genotype links is through Genome-Wide Association
Studies (GWAS), which interrogate the genome in
regions of common variability and attempt to statisti-
cally associate this variability to the phenotype of inter-
est [1]. This phenotype may be a disease trait, or in the
case of a pharmacogenetic GWAS, a drug-response phe-
notype such as the drug efficacy, adverse events, or
required dose.
Warfarin, an anticoagulant prescribed to over 30 mil-
lion patients annually to prevent thromboembolic events,
is a drug with known pharmacogenetic influences [2-4].
The dose of warfarin required for an adequate level of
anticoagulation cannot reliably be predicted from clinical
factors alone. Patients on warfarin may require doses ran-
ging from less than 10 mg/week to over 100 mg/week in
order to achieve the same level of therapeutic anticoagu-
lation [2,3]. Determining the therapeutic dose is critical
because overdosing can lead to adverse events such as
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bleeding while underdosing leaves patients at risk for
thromboembolic events [5]. Genetic variations in both
pharmacokinetic and pharmacodynamic genes relevant
to warfarin impact the required dose [2]. The most
important variants influencing warfarin dose occur in
genes encoding warfarin’s target, VKORC1, and a major
metabolizing enzyme, CYP2C9 [6-8]. Dosing algorithms
using key variants from these genes along with clinical
factors can predict stable warfarin dose to some extent,
and have the potential to help avoid the adverse events
caused by prolonged “guess-and-test” dosing [2,9-11].
Approximately 30% of the variability in warfarin dose
requirement is explained by the genetics of VKORC1 and
CYP2C9. However, current dosing algorithms fail to fully
explain the variation in dose, even when using clinical
factors in addition to the genetic information. These
algorithms perform particularly poorly in African Ameri-
cans, whose decreased variation in VKORC1 and
CYP2C9 hinders dose prediction algorithms based on
variation present in European and Asian populations
[12-14].
The biological pathways involving warfarin are well
characterized, and warfarin metabolism genes show high
genetic variability not only between individuals but also
between populations, making it cumbersome to refine
the warfarin dosing equations for each specific popula-
tion [14-16]. Furthermore, rare variants in important
genes may have crucial effects that cannot be quantified
by traditional genome-wide association methods [17].
Aggregating information from multiple single nucleotide
polymorphisms (SNPs), that individually do not show
significant association with phenotypes of interest can
improve our power to detect important variation. For
example, we have shown that rare variants of CYP2C9
can be pooled to create an indicator variable that signifi-
cantly improves warfarin dose prediction [18]. SNPs can
be grouped together in a data-driven manner using the
strength of association or by analyzing previously char-
acterized genes and pathways. Data-driven methods
select the most promising (nearly significant) SNPs and
combine the information from these SNPs to create a
summary statistic that can be associated with the pheno-
type of interest. In this setting, machine learning
approaches, including random forest regression, boosted
regression tree, and support vector regression, can be
used to select the subset of SNPs and clinical covariates
for predicting phenotypes [19,20]. However, these data-
driven methods are at risk of overfitting the data, produ-
cing a model not generalizable to other datasets or
populations [20,21]. Moreover, statistical learning meth-
ods can be biased by LD structure and minor allele fre-
quencies, requiring additional pre-processing [22].
Biologically-driven methods use information from
known pathways to group SNPs together, with the
assumption that the SNPs may have similar effects on
phenotype and thus can be aggregated. Such methods
allow for the combination of SNPs that may not be sig-
nificant alone, but in aggregate, are associated with
pathway dysfunction. Biologically-driven pathway-based
methods have been used for analyzing gene expression
data, proteomic data, and are now emerging as a mode
of analysis for genotyping and sequencing data [23][24].
Pathway-based methods group mutations from genes
in a biologically relevant pathway [24]. For instance,
Baranzini et al. combined nominally-significant SNPs
(with p< 0.05) in a MS GWAS to create gene groupings
and then compared these groupings to characterized
interaction networks to find sub-networks that were
enriched for MS genes. They identified putative patho-
genesis pathways that were consistent with the biologi-
cal systems thought to be important in Multiple
Sclerosis [25]. Similarly, a pathway analysis of the Well-
come Trust Case Control Consortium (WTCCC) looked
at the seven disease GWAS and used the most statisti-
cally significant SNP in each gene in order to create a
“score” metric for that gene. Using the top genes, Tor-
kamani et al. looked for pathways that were enriched for
the gene-set [26]. A pathway-based approach of studying
the pharmacogenomics of purine and pyrimidine anti-
metabolites in gene expression data revealed that analyz-
ing data using gene-sets rather than a single gene
approach was able to detect important groups of genes
that impact drug cytotoxicity [27].
These studies demonstrate the potential value of path-
way-based methods and underscore the importance of
aggregated genetic effects. However, they have focused
primarily on gene expression data and can be limited by
a SNP selection strategy that relies on individually sig-
nificant p-values from a single-locus analysis. Here, we
use biologically curated pathways, such as warfarin
metabolism, to create a statistic that can be tested for
association with warfarin dose. In particular, we aggre-
gate the mutational burden of genes in the metabolic
pathway of warfarin and demonstrate that this muta-
tional burden explains some of the missing heritability
in warfarin dose.
Several methods exist for aggregating SNPs across
genes or pathways. VAAST assigns gene scores using
both variant frequency data and amino acid substitution
data to test the association of entire genes to cases and
controls [28]. The weighted-sum method also combines
rare variants and compares the burden of mutation
between cases and controls to determine genes or path-
ways of interest [29]. In addition, we have used genotype
frequency to aggregate SNPs across a gene [30]. All of
these methods are designed to work best when low fre-
quency variants contribute greatly to gene scores [28,29].
Moreover, linkage disequilibrium (LD) confounds the
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ability to aggregate variants since multiple variants may be
effectively carrying the same “information” and including
them together may amount to double counting and over-
estimation of association strength. Some methods use per-
mutation testing in order to address this; however, permu-
tation testing does not properly account for LD since it
considers correlated variables to be independent. The
alternative is to remove SNPs that are in LD above an
arbitrary threshold cutoff, but this approach leads to a sig-
nificant loss of information [31]. Our method accounts for
LD structure by using a tree-based weighting scheme initi-
ally developed in the context of sequence analysis [32].
Methods
Data sources
We used three data sets from prior studies: all subjects
were on stable doses of warfarin with repeated INR
measurements between 2-3.
1. Genotypes for 188 patients of European descent with
a stable warfarin dose and clinical covariates were
obtained from Cooper et al [33]. Samples were genotyped
using the Illumina HumanHap 550k, version 3 BeadChip
(Illumina, San Diego, CA). SNPs with minor alleles in
less than 4 samples (1.3% allele frequency) were excluded.
Average call rate for SNPs was 98.8% [33].
2. We obtained genotypes from 233 venous-throm-
boembolism patients of European descent on warfarin
from the Malmo Thrombophilia Study [34]. These sub-
jects were genotyped on the Illumina 670 chip (Illumina,
San Diego, CA). SNPs with a minor allele frequency
(MAF) below 1%, MAF between 1 and 3% and call rate
under 99%, and MAF over 3% and call rate below 98%
were excluded. All included samples had a call rate
above 95%. Ethnic outliers were removed using principle
component analysis with Hapmap3 samples.
3. We obtained genotypes from 342 African Ameri-
cans (the IWPC GWAS) from different IWPC sites.
Subjects were genotyped using the Illumina 610 Quad
BeadChip at the RIKEN Center for Genomic Medicine
in Yokohama, Japan. SNPs with less than 2% minor
allele frequency were excluded except for SNPs in
VKORC1 and CYP2C9, because of evidence suggesting
their possible involvement in warfarin dosing. Data col-
lection and quality control were based on previously
described IWPC protocols [2,35-37].
For each dataset, PCA was performed on the genotype
data using the pca_module package (version 1.1.02) for
Python (version 2.7.1).
Constructing a pathway score: gene aggregation, LD
weighting methods, and pathway mapping
Aggregate Number of Minor Alleles (A#m) sums the
number of minor alleles observed in a given gene (with
each individual position having a maximum score of 2).
It assigns a point to the gene whenever a SNP is the
minor allele, or two if the SNP is homozygous for the
minor allele (Figure 1). Major alleles are derived from
the control population and whenever any allele that is
not a major allele appears, a point is given to the gene’s
score. In the case of no control population, (e.g. both
high drug dose and low drug dose populations), the
major alleles are derived across the entire population.
We obtained the major alleles using plink (version 1.07)
over the entire population of each individual dataset
(e.g. Cooper et. al. for Cooper major alleles).
To account for LD, we used an algorithm previously
developed for protein sequence similarity to weight a
SNP based on its LD with nearby SNPs [32]. We clus-
tered SNPs using the LD r2 as the similarity metric.
SNPs were clustered using single linkage clustering
(where the shortest distance between any two leaves of
a cluster is used as the cluster difference). The resulting
clusters were used to create a bifurcating tree that
relates all loci using LD (Figure 2). LD (r2) for each SNP
was calculated for all pathway SNPs within 1 Mb using
plink (version 1.07). Once clustered, we used the Ger-
stein-Sonnhammer-Chothia algorithm to compute the
weights of each leaf node (SNP) [32]. This algorithm
downweights overrepresented sequences; in this case,
SNPs in LD get downweighted because they carry
Figure 1 Aggregate number of minor alleles (A#m) scoring gives each gene 1 point for every minor allele, and then allows us to
compare the phenotype to the scores across the warfarin metabolic pathway.
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similar information. The LD-weighted score of each
pathway was determined by summing the LD-weight of
each minor allele in each given SNP (Figure 3).
We mapped SNPs to genes using dbSNP based on
build hg19 of the human genome. For NCBI’s hg19, we
used the default feature set (introns, exons) of all genes
and added 10,000 bases upstream (5’) and 3,000 bases
downstream (3’) in order to capture regulatory regions.
We determined drug metabolic pathway by selecting the
metabolic enzymes in PharmGKB’s warfarin pharmacoki-
netic pathway (PA145011113) and the drug target pathway
by using PharmGKB’s warfarin pharmacodynamic pathway
Figure 2 LD was calculated between SNPs within 1000 kb in the pathway. SNPs were clustered based on the LD r2 values. We calculated
the weights of each leaf node (SNP) using the Gerstein-Sonnhammer-Chothia algorithm.
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(PA145011114), available for download at http://pharmgkb.
org[38,39].
Pathway and weighting method validation and
replication
We performed several tests using our pathway method to
assess how variation in warfarin metabolizing enzymes
influenced dose prediction and the effectiveness of our
weighted pathway metric. First, we applied our pathway
method in a cohort of European descent to test the sig-
nificance of pathway-level variation in predicting dose.
Next, we dissected the pathway score into two pieces –
CYP2C9 and the rest of the pathway and tested how
these two separate variables predicted dose. This helped
determine whether or not the pathway was being driven
by CYP2C9, which is known to contain many important
warfarin variants [2,8]. Then we tested whether our bio-
logically derived warfarin metabolic pathway was empiri-
cally significant through 100 permutations of random
biological pathways using the Cooper et al. data. We then
predicted dose in another cohort of European ancestry
using all available covariates and the pathway score. To
show broad population applicability, we applied our path-
way score to predict dose in an African American cohort.
We evaluated clinical utility, by using the pathway score
as a variable for the warfarin pharmacogenetic equation
in the African American cohort (the only cohort with all
the pharmacogenetic equation variables available) [2].
Finally, to demonstrate the generalizability of our
weighted pathway method, we compared weighting SNPs
based on LD vs. pruning SNPs at various LD cutoffs.
Pathway method validation in Cooper et al. cohort
We produced the A#m score for the warfarin metabolic
and pharmacodynamic pathway in a population of 188
patients (182 of European descent and 6 of Hispanic des-
cent) on warfarin. We used a linear regression to model
warfarin dose with the warfarin metabolic pathway A#m
and known clinical and genetic covariates: age, weight,
race (principal components 1 and 2 of the genotype
data), amiodarone, losartan, VKORC1 (rs9923231) and
CYP2C9 status (carrier or homozygote for *3; *2 variant
Figure 3 LD-weighted A#m scores are calculated by taking the sum of all minor alleles multiplied by their respective weights. In this
case, the SNPs in the black box are in tight LD, while the SNPs in the green box are in moderate LD. With SNP weighting, rather than pruning
the SNPs in LD, SNPs are weighted based on the contribution of independent information to the A#m score.
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was not genotyped and could not be imputed from the
available data). We excluded nineteen subjects who were
missing one of the above covariates. We used an
ANOVA to test the difference between the models
including and not including the pathway score. All statis-
tical analyses were performed using the R statistical pack-
age (version 2.10.1).
Pathway method validation in Cooper et al. cohort
without CYP2C9
We removed CYP2C9 scores from the pathway score in
the Cooper et al. data. Then, we modeled warfarin dose
using a linear regression with the aforementioned clini-
cal and genetic covariates and individually added either
the CYP2C9 A#m score or warfarin metabolic A#m
score without CYP2C9 as covariates. All statistical ana-
lyses were performed using the R statistical package
(version 2.10.1).
Post hoc evaluation of 100 permutations of random
biological pathways in the Cooper et al. data
We ran 100 permutations of random pathways from a
combination of the PharmGKB, Biocarta, and Pathway
Interaction Database using MySQL (version 5.1.14). We
calculated the score for each random pathway using the
A#m method previously described using the Cooper et
al. data. We then modeled warfarin dose using a linear
model with the previously mentioned genetic and clini-
cal covariates and each pathway. We used the random
pathways to compute a background distribution of cor-
relations. The empirical p-values were then estimated
from this distribution, and reported in addition to tradi-
tional statistical tests.
Pathway method replication in IWPC Malmo cohort
We also applied pathway scores in another cohort of 233
individuals of European descent genotyped through the
International Warfarin Consortium (IWPC). For the cov-
ariates, we used age, height, weight, principle component
1, principle component 2, rs1799853 (CYP2C9 *2),
rs1057910 (CYP2C9 *3), rs9923231 (VKORC1 -1639
G>A), and rs9934438 (VKORC1 1173 C>T). The
VKORC1 SNPs were in perfect LD, and thus, only one
was used in the regression. We excluded ten subjects
because they were missing some of the above covariates.
Amiodarone and aspirin status were not available.
Pathway method replication in IWPC African American
GWAS cohort
We replicated this method in a population of African
Americans genotyped by the International Warfarin
Pharmacogenetic Consortium (IWPC). We used a simi-
lar set of covariates as used by the IWPC warfarin phar-
macogenetic equation with the addition of our pathway
scoring metric [2]. These covariates were age, height,
weight, race (principal components 1 and 2 of the geno-
typing data as ancestry), use of aspirin, amiodarone,
rs1799853 (CYP2C9 *2), rs1057910 (CYP2C9 *3),
rs9923231 (VKORC1 -1639 G>A), and rs9934438
(VKORC1 1173 C>T). The VKORC1 SNPs were in per-
fect LD, and thus, only one was used in the regression.
None of the patients were on enzyme inducers (carba-
mazepine, rifampin, phenytoin). We excluded 40 sub-
jects that were missing one of the above covariates.
Metabolic pathway score as a covariate in the IWPC
dosing equation in the IWPC African American GWAS
Cohort
We calculated the predicted dose of each individual in
the IWPC African American cohort using the IWPC
dose equation [2]. We then calculated the residual dose
by subtracting the IWPC predicted dose from the actual
dose. We used a linear regression to model the residual
dose with the A#m pathway score. The Cooper et al. and
IWPC Malmo cohorts were missing key covariate infor-
mation necessary for the IWPC pharmacogenetic equa-
tion, and thus, we were unable to calculate an IWPC
predicted dose for these groups.
Weighting method validation in Cooper et al. data and
IWPC African American GWAS with LD-pruning
We LD-pruned the Cooper et. al. pathway SNPs and the
IWPC African American GWAS pathway SNPs at incre-
mental r2 cutoffs from 0.1 to 0.9. Variants were pruned
using plink v1.07 with pairwise genotypic correlations
using the default window size of 50 SNPs and a sliding
window of 5 SNPs.
We used the resulting sets of pruned SNPs to generate
A#m scores without weighting. We modeled warfarin
dose using a linear regression with the aforementioned
clinical and genetic covariates with the A#m scores gen-
erated at the different pruning r2 cutoffs.
Results
Known metabolic pathway aggregation improves dose
prediction in 169 individuals of European descent
The Cooper et al. cohort included 188 patients (182 of
European descent and 6 of Hispanic descent) on warfarin
doses ranging from 1 mg/day to 15.54 mg/day. A sum-
mary of the patient demographic data of the Cooper et
al. cohort is available in Table 1. Nineteen observations
were deleted due to missing data, and a comparison of
demographic data between included and excluded data is
in Additional file 1 Table S1.
The A#m metabolic pathway consisted of 49 SNPs in
7 genes (Additional file 1 Table S2), and the A#m score
distribution can be found in Figure S1. We found that
the A#m metabolic pathway score was a significant
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predictor of the stable warfarin dose (F = 5.1708, p =
0.0244) (Table 1). We had an improvement of 1.4% in
adjusted r2 with the addition of the weighted pathway
scores (0.466 to 0.48). The A#m target (pharmacody-
namic) pathway was not a statistically significant predic-
tor of warfarin dose and was not tested in the subsequent
cohorts.
Metabolic pathway score is not driven by CYP2C9 score
When CYP2C9 scores were calculated separately from
the metabolic pathway and both were used as covariates,
neither CYP2C9 scores nor pathway scores were statisti-
cally significant, though the A#m pathway scores with-
out CYP2C9 was marginal (p = 0.0681) (Additional file
1 Table S3). However, the full A#m pathway score is
statistically significant (p = 0.0244, Table 1). This signifi-
cance was further confirmed by 100 permutations of
random pathways, which we used to calculate an
empirical p-value cut-off of 0.07 for significance.
Metabolic pathway score marginally significant in
replication cohort of 223 individuals of European descent
The IWPC Malmo cohort included 233 individuals of Eur-
opean descent on warfarin doses ranging from 1.25 to
15.14 mg/day. Additional demographic information
related to warfarin dose covariates can be found in
Additional file 1, Table S4. Ten observations were
excluded due to missing data. For this cohort, the A#m
pathway consisted of 84 SNPs in 7 genes (Additional file 1,
Table S5), and the A#m score distribution can be found in
Figure S2. The A#m pathway score was marginally signifi-
cant (F = 3.30, p = 0.0710); coefficients and p-values for
each covariate can be found in Additional file 1 Table S4.
Metabolic pathway score improves dose prediction in a
cohort of 302 African Americans
We replicated this method in a population of African
Americans genotyped by the International Warfarin
Pharmacogenetic Consortium (IWPC). This population
consisted of 342 individuals on doses of warfarin ran-
ging from 1.43 to 17.41 mg/day. Patient demographic
data is summarized in Table 2. The metabolic pathway
was created using 122 available SNPs in 7 genes (Addi-
tional file 1, Table S6), and the A#m score distribution
can be found in Additional file 1, Figure S3. With the
IWPC African Americans, 40 observations were not
used in the analysis due to missing data; a comparison
of covariates between included and excluded data can
be found in Additional file 1 Table S7. Dose was not
significantly different between individuals included in
the analysis and individuals removed due to missing
data.
In this cohort, the A#m pathway score was signifi-
cantly predictive of warfarin dose (F = 6.175, p= 0.0135)
(Table 2). There was an improvement in adjusted r2 of
1.3 percentage points (0.259 to 0.272) with the addition
of the weighted metabolic pathway score.
Metabolic pathway score adds information to IWPC
pharmacogenetic dosing equation in a cohort of 302
African Americans
Next, we found that A#m was a statistically significant pre-
dictor (F = 5.396, p= 0.0208) of the residual dose unex-
plained by the current IWPC warfarin pharmacogenetic
equation (Table 3) [2]. The addition of the A#m PK Path-
way to the existing IWPC dose equation in a cohort of
African Americans yields a 1.4 percentage point improve-
ment in dose prediction (0.255 to 0.269).
Weighting method validation vs. LD-pruning in Cooper et
al. data and IWPC African American GWAS
We present a comparison of p-values, number of SNPs
included, and adjusted r2 values for the weighted method
vs. several LD cutoffs in Tables S8 and S9. The best
adjusted r2 value in the Cooper et. al. data was achieved at
an LD-cutoff of 0.3, with an adjusted r2 of 0.498, compared
Table 1 Cooper et al.
Covariate Mean/% Patients Standard Deviation Coefficient p-value
Age 58.7 15.7 -0.0407 6.43E-05*
Weight (lbs) 195.3 45.3 0.0109 1.32E-03*
Amiodarone 14.3% - -1.393 1.11E-03*
Losartan 9.3% - -0.420 4.14E-01
VKORC1 AG 46.6% - 2.157 1.03E-05*
VKORC1 GG 41.0% - 3.821 2.78E-13*
CYP2C9 status 29.2% - -1.330 1.77E-04*
Principal Component 1 - 38.8 -0.000389 9.19E-01
Principal Component 2 - 25.5 -0.00576 3.15E-01
A#m Metabolic Pathway 19.38 3.57 -0.0999 2.44E-02*
patient data, regression coefficients, and p-values
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to an adjusted r2 of 0.480 with the weighted method. The
highest adjusted r2 value in the IWPC African American
GWAS data was achieved with the weighted method, with
an adjusted r2 of 0.272. If LD pruning were to be used on
the IWPC African American GWAS data, an LD-cutoff of
0.6 produces the highest adjusted r2 value (0.265) among
the various cutoffs. In several cases, choice of LD cutoff
influences significance due to information loss, whereas
the weighted method produces a significant p-value.
Discussion
Previous genetic analyses of warfarin response have used
single-locus or single-gene based approaches in order to
discover candidate variants influencing dose [37,40].
Here, we have developed a method that aggregates SNPs
along a biologically important pathway known to affect
warfarin dosing – the enzymes of its metabolic pathway.
We focused on metabolic enzymes because of their simi-
lar direction of effect on warfarin – degradation. The
metabolism genes were chosen from the PharmGKB
database of manually curated drug pathways, which are
derived from biological evidence in the literature [39].
For the general application of this method to other drug
cases, PharmGKB has manually curated pathways for
drugs whose biological actions have been well studied.
For application to disease, other resources such as Bio-
Carta and the Pathway Interaction Database may be a
useful source of pathways. Here, we show that the aggre-
gate pathway effects significantly contribute to the pre-
diction of warfarin dose, and that this pathway score is
not solely driven by CYP2C9, the major warfarin metabo-
lizing enzyme (Additional file 1 Table S3).
Our method is based on the assumption that aggre-
gate effects of the mutational burden of the warfarin
metabolizing enzymes have a similar effect and direction
of effect on the overall sensitivity to warfarin. This strat-
egy assumes that minor alleles generally lead to a
decrease or loss of function. This assumption is sup-
ported by a recent systematic review of loss-of-function
variants in the human genome, which found loss-of-
function variants to consistently occur at lower frequen-
cies [41]. Moreover, our method is robust to a small
amount of error (i.e. some of the minor alleles could
result in a gain of function and not abolish the overall
signal) and was empirically observed to be valid for
CYP2C9 [18]. Furthermore, this method relies on using
biologically validated pathways for SNP aggregation.
Because of this experimental validation, such a method
would be less likely to produce false positives.
Table 2 IWPC African American GWAS Cohort patient data, regression coefficients, p-values
Covariate Mean/% Patients Standard Deviation Coefficient p-value
Age 56.81 14.66 -0.350 1.32E-07
Weight (kg) 94.55 28.07 0.136 1.27E-04
Height (cm) 171.7 10.642 0.243 0.0105
Amiodarone 4.68% - -13.155 2.02E-03
Aspirin 27.49% - -7.21 9.58E-04
VKORC1
rs9923231 GG
82.16% - - -
VKORC1 rs9923231 AG 16.96% - -7.422 3.39E-03
VKORC1 rs9923231 AA 0.88% - -31.481 1.03E-03
CYP2C9*2
rs1799853 AG
4.09% - -2.66 0.593
CYP2C9*2
rs1799853 GG








97.66% - - -
Principal Component 1 - 27.44 -0.00943 0.784
Principal Component 2 - 24.42 -0.00697 0.864
A#m Metabolic Pathway 29.71 7.25 -0.331 0.0135
Table 3 IWPC Dose Equation with the addition of A#m
pathway score
Covariate Coefficient p-value
IWPC Dose Equation 1.00 <2E-16
A#m Metabolic Pathway -0.2935 0.0208
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We avoid the information loss and biases of LD prun-
ing by using a weighting scheme based on LD. This
method allows each SNP to contribute independent
information without double counting. We found that
while LD pruning at a cutoff of 0.3 produced an A#m
pathway score with the best adjusted r2 in the Cooper
data, the weighted method produced the best adjusted r2
in the African American IWPC GWAS data. LD pruning;
however, is biased; one does not know a priori what cut-
off will produce the best results, and thus, it becomes
necessary to choose a reasonable cutoff based on prefer-
ence. For instance, the LD cutoff of 0.3, which produced
the highest adjusted r2 in the Cooper et al. data would
have produced one of the worst adjusted r2 values in the
African American IWPC GWAS data. In fact, any cutoff
below 0.5 would not have produced a statistically signifi-
cant A#m pathway score in the African American IWPC
GWAS data due to information loss. The weighted
method allows one to evaluate the data in an unbiased
manner without the need for pruning, eliminating the
arbitrary step of LD cutoff selection.
In the Cooper et al. data, our A#m pathway score is a
statistically significant predictor of dose even when using
all available covariate data (including genotype data). Since
CYP2C9 has such a large influence on warfarin dose in
individuals of European descent, we evaluated whether
CYP2C9 was driving the A#m pathway score (Additional
file 1 Table S3). Since the CYP2C9 gene score was not sta-
tistically significant, we can infer that the significance of
the entire pathway is not driven solely by variants in
CYP2C9. Furthermore, the remaining pathway score (all
metabolic enzymes except CYP2C9) was marginally signif-
icant, possibly suggesting that aggregative effects along the
rest of the pathway are an important contributor to the
significance of the overall pathway. The combinatorial
effect of the entire metabolic pathway produces a statisti-
cally significant metric for predicting dose – explaining 1.4
percentage points of the dose. Combinatorial effects in a
metabolic pathway make sense from a biological stand-
point. As Figure 4 demonstrates, a wide range of enzymes
act independently or in concert to metabolize the two war-
farin enantiomers. A change in a single enzyme that slows
down metabolism may not appear phenotypically, as the
other enzymes may compensate or mask the detriment to
the overall pathway. However, multiple minor changes in
multiple enzymes could create a situation in which the
overall pathway is slowed down, in a way that would not
have been apparent using single locus or single-gene ana-
lysis. The warfarin pharmacodynamic pathway was not a
significant predictor of warfarin dose. Biologically, this
pathway contains the warfarin target, VKORC1, and
upstream/downstream proteins that interact with
VKORC1. Many of these proteins have opposite effects on
coagulation/warfarin dose – mutations in CYP4F2 lead to
higher warfarin dose, mutations in Protein C and S lead to
greater coagulation, while mutations in Factor IX and X
lead to under coagulation [42-45]. Because the directional-
ity of each protein’s action is not the same (unlike the
metabolic enzymes, which all inactivate warfarin or its
metabolites in some way), it is not surprising that we find
no signal from the combinatorial effects of the pharmaco-
dynamic pathway. Future iterations of the method, which
assign directionality to a protein’s action, may find signal
in this pathway as well.
In the IWPC Malmo cohort, the A#m metabolic path-
way score was marginally significant (p = 0.07), suggest-
ing that the pathway score may have an effect on dose
prediction in this cohort. The SNPs used in this analysis
were different from the SNPs used in the Cooper analy-
sis, due to the use of different genotyping chips. In
order to avoid bias, we used all available SNPs in a
pathway, which can affect the pathway score if some
SNPs do not contribute to the signal and introduce
noise. Filtering SNPs based on prior biological knowl-
edge or findings may lead to a stronger signal, but will
miss effects of rare variants or SNPs that have not been
characterized. Moreover, we expect that the pathway
score to be less predictive in populations of European
descent compared to populations of African descent
because variation along the entire metabolic pathway is
lower in populations of European descent [46].
African Americans have greater genetic variation in
the cytochrome p450 enzymes making pharmacogenetic
warfarin dose prediction particularly difficult. We antici-
pated that this method would be successful in an Afri-
can American cohort, where much of the heritability in
warfarin dose has not been explained. The addition of
the A#m pathway score to the other known covariates
for warfarin dose demonstrated that the A#m pathway
was a statistically significant contributor to predicting
warfarin dose in African Americans. In both the Cooper
et. al. and African American analysis, the coefficient for
the A#m pathway was negative – consistent with our
assumptions that minor alleles lead to loss of function,
since decreased enzyme activity leads to reduced clear-
ance, resulting in a lower therapeutic dose. However, we
acknowledge that some alleles may yield a gain of func-
tion, and refining our method to take into account the
directionality of each SNP’s effect would improve our
future models.
To show clinical relevance, we calculated the pre-
dicted IWPC dose for the African Americans – this
including pharmacogenetic factors such as variants in
VKORC1 and CYP2C9. We predicted warfarin dose in
the IWPC African American GWAS data using the esti-
mated IWPC dose plus our A#m pathway score, and
showed that our A#m pathway score was a statistically
significant covariate for dose prediction beyond what is
Daneshjou et al. BMC Genomics 2013, 14(Suppl 3):S11
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predicted by the IWPC pharmacogenomic algorithm.
The pathway score was able to capture 1.4 percentage
points of the missing signal in dose prediction, demon-
strating that pathway interactions and mutational load
may be a contributor to the missing heritability in war-
farin dosing.
We used a pathway-based method to show that aggre-
gate effects along biologically important pathways could
influence a phenotype (in this case, warfarin dosing). We
were able to create an unbiased tool for downweighting
SNP contributions based on information similarity (LD),
thus eliminating the need for LD pruning prior to aggrega-
tion. Currently, we treat each SNP the same - SNPs do not
get additional upweighting if functional significance is
known. Future methods may assign additional weights to
SNPs or genes with biologically known functional rele-
vance that may have a stronger influence on the pathway
score. Our method may also have useful predictive value
for other phenotypes influenced by pathway-level changes,
such as cancer biology.
Figure 4 Warfarin pharmacokinetic pathway.
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Additional Files
Additional tables can be found in the Supplementary




RD contributed to experimental design, pathway and weighting method
implementation and statistics, and drafted the manuscript. NPT contributed
to experimental design, implementation of the LD-weighting algorithm, and
helped draft the manuscript. KJK contributed to experimental design,
statistical analysis, and helped draft the manuscript. HS created the A#m
scoring metric. SB genotyped and performed quality control on the Malmo
Cohort. JKB, TT, YN, MK, MT, NAL, LHC, MP, JAJ, and TEK genotyped and
performed quality control on the IWPC African American GWAS data. RBA
contributed to experimental design and drafted the manuscript. All authors
read and approved manuscript.
Competing interests
RBA is a founder and scientific consultant to http://Personalis.com. JKB has a
patent pending for the use of CYP4F2 in warfarin dosing.
Acknowledgements
Geoffery M. Cooper, for allowing us to use the Cooper. et. al. warfarin data.
The International Warfarin Pharmacogenetic Consortium. RD was funded by
the Howard Hughes Medical Institute Medical Fellows, Stanford School of
Medicine Medical Scholars Grant, and the Stanford School of Medicine
Medical Scientist Training Program, NPT was funded by DOESCGF. JKB is a
member of the Wisconsin Network for Health Research and funded by grant
UL155025011. LHC is funded by American Heart Association Midwest
Affiliate Grant-In-Aid (10GRNT3750024) and the University of Illinois Hans
Vahlteich Pharmacy Endowment Award. NAL was funded by the National
Heart Lung and Blood Institute (RO1HL092173) and the National Institute of
Neurological Disorders and Stroke (K23NS45598). MP is funded by K23
HL089808-01A2. MT is funded by Wisconsin Network for Health Research.
RBA is funded by. NIH/NIGMS R24 GM61374, BioX2 NSF Grant (CNS-
0619926).
Declarations
The publication costs for this article were funded by the above grants.
Author details
1Department of Genetics, Stanford University School of Medicine, Stanford,
CA 94305, USA. 2Department of Biomedical Informatics, Columbia University,
New York, NY 10032, USA. 3Biomedical Informatics Training Program,
Stanford University School of Medicine, Stanford, CA 94305, USA. 4Wellcome
Trust Sanger Institute, Hinxton, UK. 5University of Illinois at Chicago,
Department of Pharmacy Practice, Chicago, IL 60612, USA. 6Clinical Research
Center, Marshfield Clinic Research Foundation, Marshfield, WI 54449, USA.
7Research Group for Medical Informatics, Center for Genomic Medicine,
RIKEN, Tokyo, Japan. 8Aurora St. Luke’s Medical Center, Milwaukee, WI, USA.
9Department of Neurology, University of Alabama at Birmingham, AL 35294,
USA. 10University of Chicago, Department of Medicine, Chicago, IL 60637,
USA. 11University of Florida, Department of Pharmacotherapy and
Translational Research, Gainsville, FL 32610, USA. 12Department of
Bioengineering, Stanford University School of Medicine, Stanford, CA 94305,
USA.
Published: 28 May 2013
References
1. Pearson TA, Manolio TA: How to interpret a genome-wide association
study. JAMA 2008, 299:1335-44.
2. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA,
Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA: Estimation of
the warfarin dose with clinical and pharmacogenetic data. N Engl J Med
2009, 360:753-64.
3. Gage BF, Lesko LJ: Pharmacogenetics of warfarin: regulatory, scientific,
and clinical issues. J Thromb Thrombolysis 2008, 25:45-51.
4. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC: National trends
in oral anticoagulant use in the United States, 2007 to 2011. Circ
Cardiovasc Qual Outcomes 5:615-21.
5. Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin
use: a prevalent adverse effect resulting in regulatory action. Arch Intern
Med 2007, 167:1414-9.
6. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R,
Brancaccio V, Grandone E, Margaglione M: A polymorphism in the
VKORC1 gene is associated with an interindividual variability in the
dose-anticoagulant effect of warfarin. Blood 2005, 105:645-9.
7. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM,
Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE,
Altman RB: Clinical Pharmacogenetics Implementation Consortium
Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin
Pharmacol Ther 90:625-9.
8. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in
the cytochrome P450 CYP2C9 with warfarin dose requirement and risk
of bleeding complications. Lancet 1999, 353:717-9.
9. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of
pharmacogenetics and clinical factors to predict the maintenance dose
of warfarin. Thromb Haemost 2004, 91:87-94.
10. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE,
Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T,
Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL: Use of
pharmacogenetic and clinical factors to predict the therapeutic dose of
warfarin. Clin Pharmacol Ther 2008, 84:326-31.
11. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P,
Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC1
genetic polymorphism and patient characteristics upon warfarin dose
requirements: proposal for a new dosing regimen. Blood 2005,
106:2329-33.
12. Roper N, Storer B, Bona R, Fang M: Validation and comparison of
pharmacogenetics-based warfarin dosing algorithms for application of
pharmacogenetic testing. J Mol Diagn 12:283-91.
13. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J: Accuracy
assessment of pharmacogenetically predictive warfarin dosing
algorithms in patients of an academic medical center anticoagulation
clinic. J Thromb Thrombolysis 30:220-5.
14. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ: Combined CYP2C9,
VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Pharmacogenomics 11:781-91.
15. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ:
CYP2C9*8 is prevalent among African-Americans: implications for
pharmacogenetic dosing. Pharmacogenomics 2009, 10:1243-55.
16. Kudzi W, Dodoo AN, Mills JJ: Characterisation of CYP2C8, CYP2C9 and
CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009,
10-124.
17. Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common
disease through whole-genome sequencing. Nat Rev Genet 11:415-25.
18. Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A,
Altman RB: Extending and evaluating a warfarin dosing algorithm that
includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet
Genomics 20:407-13.
19. Moore JH, Asselbergs FW, Williams SM: Bioinformatics challenges for
genome-wide association studies. Bioinformatics 26:445-55.
20. Cosgun E, Limdi NA, Duarte CW: High-dimensional pharmacogenetic
prediction of a continuous trait using machine learning techniques with
application to warfarin dose prediction in African Americans.
Bioinformatics 27:1384-9.
21. Wang K, Li M, Hakonarson H: Analysing biological pathways in genome-
wide association studies. Nat Rev Genet 11:843-54.
22. Walters R, Laurin C, Lubke GH: An integrated approach to reduce the
impact of minor allele frequency and linkage disequilibrium on
variable importance measures for genome-wide data. Bioinformatics
28:2615-23.
23. Khatri P, Sirota M, Butte AJ: Ten years of pathway analysis: current
approaches and outstanding challenges. PLoS Comput Biol 8:e1002375.
Daneshjou et al. BMC Genomics 2013, 14(Suppl 3):S11
http://www.biomedcentral.com/1471-2164/14/S3/S11
Page 11 of 12
24. Ritchie MD: Using prior knowledge and genome-wide association to
identify pathways involved in multiple sclerosis. Genome Med 2009, 1-65.
25. Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D,
Wu W, Uitdehaag BM, Kappos L, Polman CH, Matthews PM, Hauser SL,
Gibson RA, Oksenberg JR, Barnes MR: Pathway and network-based
analysis of genome-wide association studies in multiple sclerosis. Hum
Mol Genet 2009, 18:2078-90.
26. Torkamani A, Topol EJ, Schork NJ: Pathway analysis of seven common
diseases assessed by genome-wide association. Genomics 2008,
92:265-72.
27. Fridley BL, Batzler A, Li L, Li F, Matimba A, Jenkins GD, Ji Y, Wang L,
Weinshilboum RM: Gene set analysis of purine and pyrimidine
antimetabolites cancer therapies. Pharmacogenet Genomics 21:701-12.
28. Yandell M, Huff C, Hu H, Singleton M, Moore B, Xing J, Jorde LB, Reese MG:
A probabilistic disease-gene finder for personal genomes. Genome Res
21:1529-42.
29. Madsen BE, Browning SR: A groupwise association test for rare mutations
using a weighted sum statistic. PLoS Genet 2009, 5:e1000384.
30. Tatonetti NP, Dudley JT, Sagreiya H, Butte AJ, Altman RB: An integrative
method for scoring candidate genes from association studies:
application to warfarin dosing. BMC Bioinformatics 11(Suppl 9):S9.
31. Moskvina V, Schmidt KM, Vedernikov A, Owen MJ, Craddock N, Holmans P,
O’Donovan MC: Permutation-based approaches do not adequately allow
for linkage disequilibrium in gene-wide multi-locus association analysis.
Eur J Hum Genet 20:890-6.
32. Gerstein M, Sonnhammer EL, Chothia C: Volume changes in protein
evolution. J Mol Biol 1994, 236:1067-78.
33. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI,
Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE,
Rieder MJ: A genome-wide scan for common genetic variants with a
large influence on warfarin maintenance dose. Blood 2008, 112:1022-7.
34. Isma N, Svensson PJ, Gottsater A, Lindblad B: Prospective analysis of risk
factors and distribution of venous thromboembolism in the population-
based Malmo Thrombophilia Study (MATS). Thromb Res 2009, 124:663-6.
35. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT,
Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF,
Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE,
Johnson JA, Klein TE, Wagner MJ: Warfarin pharmacogenetics: a single
VKORC1 polymorphism is predictive of dose across 3 racial groups.
Blood 115:3827-34.
36. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA,
Nicolae D, Cox NJ: The missing association: sequencing-based discovery
of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in
African Americans. Clin Pharmacol Ther 89:408-15.
37. Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-
Michaels K, Viana MA, Shapiro NL, Nutescu EA: Association of the GGCX
(CAA)16/17 repeat polymorphism with higher warfarin dose
requirements in African Americans. Pharmacogenet Genomics 22:152-8.
38. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE: From
pharmacogenomic knowledge acquisition to clinical applications: the
PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark
Med 5:795-806.
39. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF,
Altman RB, Klein TE: Pharmacogenomics knowledge for personalized
medicine. Clin Pharmacol Ther 92:414-7.
40. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA,
Cavallari LH: Decreased warfarin clearance associated with the CYP2C9
R150H (*8) polymorphism. Clin Pharmacol Ther 91:660-5.
41. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K,
Jostins L, Habegger L, Pickrell JK, Montgomery SB, Albers CA, Zhang ZD,
Conrad DF, Lunter G, Zheng H, Ayub Q, DePristo MA, Banks E, Hu M,
Handsaker RE, et al: A systematic survey of loss-of-function variants in
human protein-coding genes. Science 335:823-8.
42. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P,
Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR,
Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK: CYP4F2
genetic variant alters required warfarin dose. Blood 2008, 111:4106-12.
43. Feero WG: Genetic thrombophilia. Prim Care 2004, 31:685-709, xi.
44. Carcao MD: The diagnosis and management of congenital hemophilia.
Semin Thromb Hemost 38:727-34.
45. Vanden Hoek AL, Talbot K, Carter IS, Vickars L, Carter CJ, Jackson SC,
Macgillivray RT, Pryzdial EL: Coagulation factor X Arg386 specifically
affects activation by the intrinsic pathway: a novel patient mutation. J
Thromb Haemost 10:2613-5.
46. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK,
Acton RT: Influence of CYP2C9 and VKORC1 on warfarin dose,
anticoagulation attainment and maintenance among European-
Americans and African-Americans. Pharmacogenomics 2008, 9:511-26.
doi:10.1186/1471-2164-14-S3-S11
Cite this article as: Daneshjou et al.: Pathway analysis of genome-wide
data improves warfarin dose prediction. BMC Genomics 2013 14(Suppl 3):
S11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Daneshjou et al. BMC Genomics 2013, 14(Suppl 3):S11
http://www.biomedcentral.com/1471-2164/14/S3/S11
Page 12 of 12
